VivoSeq
Metabolic & Endocrine

Cushing Disease

1

Pipeline Programs↗

4

Active Trials↗

0

Companies Involved↗

Cushing Disease is an early-stage landscape with 1 program across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

20/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Fluoro-O-(2) Fluoroethyl-L-Tyrosine (FET) PET

Mayo Clinic

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Enrolling by invitation1 · 20%
Withdrawn1 · 20%

Clinical Trials

Trial Activity

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Recruiting·UUniversity of California, Los Angeles·Phase 2·NCT05971758·20 enrolled
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Recruiting·—·Phase 2·NCT03774446·13 enrolled
Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease - a Prospective Diagnostic Study
Enrolling by invitation·UUniversity Hospital, Basel, Switzerland·Preclinical·NCT07108244·43 enrolled
Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015
Withdrawn·UUniversity Hospital, Brest·N/A·NCT03297892
18Fluoro-O-(2) Fluoroethyl-L-tyrosine (FET) PET For Localization Of Pituitary Adenomas In Patients With Cushing Disease
Recruiting·MMayo Clinic·Phase 1·NCT07460232·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)